Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT04534439

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Aptabio Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT04534439
  • EudraCT 2019-004155-37
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Bulgaria, Czechia, Hungary, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04534439. Randomized; quadruple masking; primary purpose treatment. Start 2020-08-24 (actual); primary completion 2021-07-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
Condition
Diabetic Nephropathies
Condition
Diabetes Mellitus, Type 2
Condition
Nephropathy, Diabetic
Intervention (Drug)
APX-115
Intervention (Drug)
Placebo
Lead sponsor
Aptabio Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04534439
Content hash
c165c55bf60cce9ac539d5a3a6185173517447a491645d15fc2fcfdc903ca75d